AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Respiratory & Immunology (R&I) by Year
Respiratory & Immunology (R&I) — Worldwide product sales ($M) ($M)
AstraZeneca Respiratory & Immunology (R&I): $8,167M in FY2025, up 10.1% from a year earlier. That is the highest of the 10 years on record here.
Where the FY2025 figure comes from
“|| R&I | 8,167 | 10 | 10 | 3,840 | 12 | 1,823 | (4) | (3) | 1,701 | 20 | 16 | 803 | 17 | 18”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K Quarterly & Form 20-F Product Sales by Therapy Area & Region Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Respiratory & Immunology (R&I) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8,167 | +10.1% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 7,416 | +21.4% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 6,107 | +5.9% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 5,765 | -4.5% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 6,034 | +12.6% | Form 6-K FY2021Q4 Earnings Release ↗ |
| FY2020 | Dec 31, 2020 | 5,357 | -0.6% | Form 6-K FY2020Q4 Earnings Release ↗ |
| FY2019 | Dec 31, 2019 | 5,391 | +9.8% | Form 20-F (filed 2020-03-03) ↗ |
| FY2018 | Dec 31, 2018 | 4,911 | +4.4% | Form 20-F (filed 2019-03-05) ↗ |
| FY2017 | Dec 31, 2017 | 4,706 | -1.0% | Form 20-F (filed 2019-03-05) ↗ |
| FY2016 | Dec 31, 2016 | 4,753 | – | Form 20-F (filed 2019-03-05) ↗ |
Breakdown
What makes up respiratory & Immunology (R&I)
- Respiratory & Immunology (R&I) — Worldwide YoY actual (%)10.0% · FY2025
- Respiratory & Immunology (R&I) — Worldwide YoY CER (%)10.0% · FY2025
- Respiratory & Immunology (R&I) — US product sales ($M)3,840 · FY2025
- Respiratory & Immunology (R&I) — Emerging Markets product sales ($M)1,823 · FY2025
- Respiratory & Immunology (R&I) — Europe product sales ($M)1,701 · FY2025
- Respiratory & Immunology (R&I) — Established RoW product sales ($M)803 · FY2025
- Fasenra (benralizumab) — Worldwide product sales ($M)1,981 · FY2025
- Breztri Aerosphere (budesonide/glycopyrronium/formoterol) — Worldwide product sales ($M)1,199 · FY2025
- Symbicort (budesonide/formoterol) — Worldwide product sales ($M)2,885 · FY2025
- Tezspire (tezepelumab — direct product sales) — Worldwide product sales ($M)458 · FY2025
- Saphnelo (anifrolumab) — Worldwide product sales ($M)686 · FY2025
- Airsupra (albuterol/budesonide) — Worldwide product sales ($M)166 · FY2025
- Pulmicort (budesonide) — Worldwide product sales ($M)518 · FY2025
- Other Respiratory & Immunology medicines — Worldwide product sales ($M)274 · FY2025
Cite this data
StockData. (2026). AstraZeneca Respiratory & Immunology (R&I) ($M), annual FY2016–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/ta-ri-world
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.